Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Receivables - Net: 2019-2025

Historic Receivables - Net for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Sep 2025 value amounting to $106.4 million.

  • Catalyst Pharmaceuticals' Receivables - Net rose 82.63% to $106.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.4 million, marking a year-over-year increase of 82.63%. This contributed to the annual value of $65.5 million for FY2024, which is 22.35% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Receivables - Net stood at $106.4 million for Q3 2025, which was up 61.56% from $65.9 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Receivables - Net high stood at $106.4 million for Q3 2025, and its period low was $5.6 million during Q1 2021.
  • Moreover, its 3-year median value for Receivables - Net was $58.3 million (2024), whereas its average is $60.2 million.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Receivables - Net fell by 19.04% in 2021 and then surged by 414.61% in 2023.
  • Quarterly analysis of 5 years shows Catalyst Pharmaceuticals' Receivables - Net stood at $6.6 million in 2021, then spiked by 57.71% to $10.4 million in 2022, then skyrocketed by 412.64% to $53.5 million in 2023, then rose by 22.35% to $65.5 million in 2024, then surged by 82.63% to $106.4 million in 2025.
  • Its Receivables - Net was $106.4 million in Q3 2025, compared to $65.9 million in Q2 2025 and $71.3 million in Q1 2025.